Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10395695 | 0.90 | KMT2A (0.46) | KMT2AMEN1NR1I2P2RX7ABCB11 | |
| SCHEMBL5567164 | 0.90 | KMT2A (0.46) | KMT2AMEN1NR1I2P2RX7ABCB11 | |
| SCHEMBL10395311 | 0.86 | P2RX7 (0.43) | KMT2AMEN1NR1I2P2RX7ABCB11 | |
| SCHEMBL5561470 | 0.85 | KMT2A (0.47) | KMT2AMEN1NR1I2P2RX7ABCB11 | |
| SCHEMBL7909905 | 0.84 | KMT2A (0.58) | KMT2AMEN1NR1I2P2RX7ABCB11 | |
| SCHEMBL8603426 | 0.82 | KMT2A (0.54) | KMT2AMEN1NR1I2P2RX7ABCB11 | |
| SCHEMBL6480175 | 0.82 | MEN1 (0.40) | KMT2AMEN1NR1I2P2RX7ABCB11 | |
| SCHEMBL27566778 | 0.81 | P2RX7 (0.46) | KMT2AMEN1NR1I2P2RX7ABCB11 | |
| SCHEMBL6479192 | 0.80 | KMT2A (0.50) | KMT2AMEN1NR1I2P2RX7ABCB11 | |
| SCHEMBL27571832 | 0.80 | KMT2A (0.46) | KMT2AMEN1NR1I2P2RX7ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951857-B2 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD | 2005-10-04 | — | — | US | disclosed |
| US-6743792-B2 | ANTIINFLAMMATORY AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-01 | — | — | US | disclosed |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD (BE) | 2003-11-27 | — | — | US | disclosed |
| US-20020042416-A1 | Antiinflammatory agents | FREYNE EDDY JEAN EDGARD (BE) | 2002-04-11 | — | — | US | disclosed |
| EP-1003729-A1 | 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999002504-A1 | 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| US-4952570-A | ANTIPROTOZOA AGENTS; COCCIDIOSIS | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-08-28 | — | — | US | disclosed |
| US-4912106-A | 5,6-Dihydro-2-(substituted phenyl)-1,2,4-triazine-3,5,(2H,4H)-diones and their use as protozoa combating agents | JANSSEN PHARMACEUTICA N. V. FRAME-319 (BE) | 1990-03-27 | — | — | US | disclosed |
| US-4767760-A | Anti-protozoal 5,6-dihydro-2-(substituted phenyl)-1,2,4-triazine-3,5(2H,4H)-dione derivatives, compositions, and method of use therefor | JANSSEN PHARMACUETICA N.V. (BE) | 1988-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042416-A1 | Antiinflammatory agents | CCR1, CCR6, FPR1 | KMT2A 4147/4885MEN1 4743/4885NR1I2 384/4885 |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | IL6, CCR1, CCR6 | KMT2A 3682/4885MEN1 4804/4885NR1I2 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.